Eltrombopag for use in children with immune thrombocytopenia.
Sign Up to like & getrecommendations! Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2017010660
Abstract: Eltrombopag is currently the only US Food and Drug Administration-approved thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia (ITP) in children. This oral, once-per-day therapy has shown favorable efficacy and adverse effect profiles… read more here.
Keywords: thrombocytopenia; eltrombopag use; immune thrombocytopenia; use children ... See more keywords